|
|
| Enbrel |
All Financial Data in US $ (mln) |
|
Word Search (Top 10 - by date)
|
Amgen's 2014 Revenues Increased 7 Percent To $20.1 Billion And Adjusted Earnings Per Share (EPS) Increased 14 Percent To $8.70
Amgen
(January 27, 2015)
|
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2014 RESULTS; PROVIDES 2015 FINANCIAL GUIDANCE
Pfizer
(January 27, 2015)
|
| Global Biosimilars Industry 2015 Trends & Opportunities Discussed in New Research Report
(January 25, 2015)
|
European Medicines Agency Accepts Samsung Bioepis' Enbrel(R) Biosimilar Candidate, SB4, for Regulatory Review
Samsung Bioepis
(January 21, 2015)
|
Novartis Cosentyx(TM) is the First IL-17 Inhibitor to Receive EU Approval for First-line Treatment of Moderate-to-severe Psoriasis Patients
Novartis
(January 19, 2015)
|
| Cure Duchenne Seeds Collaborative Project to Analyze the Natural History of Duchenne Muscular Dystrophy
(January 13, 2015)
|
Dermira and UCB Announce Start of Phase 3 Program for CIMZIA® (certolizumab Pegol) in Psoriasis
Dermira
(January 08, 2015)
|
Dermira and UCB announce start of Phase 3 program for CIMZIA® (certolizumab pegol) in psoriasis
UCB
(January 08, 2015)
|
Coherus BioSciences Reports Third Quarter 2014 Financial and Operating Results
Coherus BioSciences
(December 15, 2014)
|
Head-to-head Psoriasis Study Demonstrates Superiority of Novartis Cosentyx(TM) to Stelara® in Clearing Skin
Novartis
(December 12, 2014)
|
|
|
|
|
EvaluatePharma® - the premier source for pharma and biotech analysis.
Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.
|
|
Product Sales Summary 2010/11
|
|
Annual Sales WW - Sales
|
Growth per Year (%)
|
|
Rank1 |
Generic Name
|
Therapeutic Subcategory
|
2010 |
2011 |
2011 |
| Enbrel2 |
|
|
|
7,257 |
7,892 |
|
+9% |
|
|
Note: Shaded Cells3 |
|
|
|
Clinical Trial Coverage: No. of Trials involving Product
|
|
|
|
Welcome
Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.
Explore Evaluate
Partnering
EvaluatePharma® now includes Partnering Opportunities - products available for licensing.
Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.
Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.
Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.
Register to access more FREE content:
- 2011 Product Sales analysis
- Download analysis into Excel
- Search 2 yrs of company press releases
Register for Free Analysis
Register to access more free insights and analysis from Evaluate.
Register Now
|
|
|
|